Equillium (EQ) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on therapies for serious autoimmune and inflammatory disorders; lead program EQ504 is an AhR-modulating small molecule.

• EQ504 entered a Phase 1 placebo-controlled proof-of-mechanism study in October 2026; topline data anticipated in Q2 2027, with a UC proof-of-concept study targeted for H2 2027 subject to supportive data.

• EQ504 is initially targeted at UC and other GI diseases, with an oral colon-targeted formulation; inhaled development for inflammatory lung diseases is in IND-enabling activities.

• EQ302 is a nonclinical oral, selective bispecific inhibitor of IL-15 and IL-21; IND-enabling development has begun, with celiac disease among potential indications.

Use of proceeds and capital allocation

• No proceeds from selling-stockholder resales; issuer covers registration costs, while selling holders pay sale-related commissions, transfer taxes and similar costs.

• Cash exercise of the pre-funded warrants would provide only the nominal $0.0001-per-share exercise price.

Risk factors and disclosures

• Investment carries a high degree of risk; risks in the latest FY2025 Form 10-K, subsequent 2026 Form 10-Qs and later SEC filings are incorporated by reference.

• EQ504 study timing and favorable results are uncertain; actual outcomes may differ materially from forward-looking statements, and no update is promised except as required by law.